Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRKAd5 HIV-1 gag/pol/nef vaccine in acute/recent HIV
NCT00183261Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2006
- Primary completion
- Aug 2007
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of MRKAd5 HIV-1 gag/pol/nef vaccine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2006; status: completed.
02
Drugs
MRKAd5 HIV-1 gag/pol/nef vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00183261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183261.